Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Quinolone Derivative
100%
Triazole Derivative
100%
Nitrofurantoin
100%
Fosfomycin
100%
Lefamulin
100%
Tedizolid
100%
Polymyxin
100%
Enoxaparin
100%
Erectile Dysfunction
100%
Phosphodiesterase V Inhibitor
100%
Cotrimoxazole
100%
Daptomycin
100%
Glycopeptide
100%
Antiinfective Agent
100%
Drug Interaction
100%
Aminoglycoside
100%
Macrolide
100%
Human Immunodeficiency Virus Infection
100%
Oxazolidinone Derivative
100%
Clindamycin
100%
Drug-Drug Interaction
100%
Trimethoprim
100%
Blood Stasis
100%
Pharmacodynamics
100%
Echinocandin
100%
Pharmacokinetics
100%
Low Molecular Weight Heparin
66%
Andexanet Alfa
50%
Tranexamic Acid
50%
Idarucizumab
50%
Aminocaproic Acid
50%
Anticoagulant Agent
50%
Warfarin
50%
Observational Study
50%
Tissue Plasminogen Activator
50%
Thromboembolism
33%
Phosphodiesterase V
25%
Proteinase Inhibitor
25%
Antifungal Agent
23%
Infection
23%
Clinical Pharmacokinetics
23%
Venous Thromboembolism
16%
Acute Coronary Syndrome
16%
Bleeding
16%
Prevalence
16%
Human Study
15%
Rezafungin
15%
Invasive Candidiasis
15%
Fluconazole
15%
Keyphrases
Retrospective Cohort Study
100%
Fluoroquinolones
100%
Polymyxin
100%
Antibacterial Drugs
100%
Fosfomycin
100%
Lefamulin
100%
Nitrofurantoin
100%
Tedizolid
100%
Index Classes
100%
Glycopeptides
100%
Body Mass Index
100%
Trimethoprim-sulfamethoxazole (TMP-SMX)
100%
Daptomycin
100%
Aminoglycosides
100%
Clindamycin
100%
Enoxaparin
100%
Oxazolidinone
100%
Trimethoprim
100%
Morbidly Obese Patients
100%
Macrolides
100%
Coagulation/fibrinolysis
100%
Therapeutic Dose
66%
Training Workshop
66%
Supratherapeutic
50%
Direct-acting Anticoagulants
50%
Fourth-year Students
33%
Low Molecular Weight Heparin
16%
Three-body
16%
Bleeding
16%
Electronic Chart
16%
Venous Thromboembolism
16%
Acute Coronary Syndrome
16%
Level Monitoring
16%
Chart Review
16%
Recommended Dose
16%
Subtherapeutic
16%
Weight-based
16%
Major Bleeding
16%
Patient Will
16%
Record Data
16%
Dose Capping
16%
Rezafungin
15%
Novel Antifungals
15%
Antibiotic Prescribing
9%
Interaction Length
8%
Special Patient Populations
7%
Rare Fungal Infection
7%
Randomized Comparative Study
7%
Emerging Pathogens
7%
Pharmacodynamic Target Attainment
7%